Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 1, 2013
- Accepted in final form June 12, 2013
- First Published September 18, 2013.
Article Versions
- Previous version (September 18, 2013 - 13:01).
- You are viewing the most recent version of this article.
Author Disclosures
- Clemens Warnke, MD*,
- Anne K. Mausberg, PhD*,
- Mark Stettner, MD,
- Thomas Dehmel, MSc,
- Lina Nekrich,
- Gerd Meyer zu Horste, MD,
- Hans-Peter Hartung, MD,
- Anna Fogdell-Hahn, PhD,
- Ortwin Adams, MD and
- Bernd C. Kieseier, MD
- Clemens Warnke, MD*,
NONE
NONE
CW has received compensation for travel expenses from TEVA Pharma.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS)fellowship stipend to Dr. Warnke, 2011 and 2012
NONE
NONE
NONE
NONE
NONE
NONE
- Anne K. Mausberg, PhD*,
NONE
NONE
travel expenses from Grifols
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark Stettner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Dehmel, MSc,
(1) Novartis Pharma Scientific Advisory Board Meeting, San Francisco, March 2013
NONE
(1) Novartis Pharma, financial support for travel and congress registration fee (2) Bayer HealthCare, financial support for travel and congress registration fee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lina Nekrich,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gerd Meyer zu Horste, MD,
NONE
NONE
(1) biogen idec, travel funding (2) TEVA pharmaceuticals, travel funding
(1) European Journal of Medical Research, associate editor, 2012
(1) US registration 60/969,381 “9-amino-acridine derivates and method of treating autoimmune diseases using the same”; patent to treat autoimmune disorders with novel compound Quinpramin
NONE
NONE
NONE
NONE
NONE
NONE
(1) Grifols, project funding
NONE
NONE
(1) German Research Association (DFG), project funding (2) Fritz-Thyssen foundation, project funding
NONE
NONE
NONE
NONE
NONE
NONE
- Hans-Peter Hartung, MD,
Novartis; Merck Serono; Teva; Biogen Idec; Roche; Genzyme; BayerHealthcare; Sanofi
NONE
Speaker Honoraria from: Biogen Idec Teva Sanofi Aventis Merck Serono Novartis ; Bayer Schering
board member: annals of neurology, journal of neuroimmunology, multiple sclerosis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna Fogdell-Hahn, PhD,
NONE
NONE
Informa March 2013 London, UK, invited speaker, travel and hotel paid.
Associated editor from 2010 for: Drugs and Therapy Studies (http://www.pagepress.org/journals/index.php/dts)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) BiogenIdec unrestriced research grant (2) Merck Serono unrestricted research grant (3) Sanofi Aventis unrestricted research grant
NONE
NONE
(1) IMI - Innovative Medicines Initiative,ABIRISK.
NONE
NONE
NONE
NONE
NONE
NONE
- Ortwin Adams, MD and
On April 11th 2013 I participated on a expert meeting of Biogen Idec in Munich about the topic “Risk stratification for developing PML of MS patients with Natalizumab. I was not involved in any strategic or other decisions of Biogen Idec. I got a honorarium for participating.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bernd C. Kieseier, MD
Commercial - Biogen Idec Commercial - Novartis Commercial - Sanofi Aventis Commercial - Roche Commercial - Merck Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial - Biogen Idec Commercial - Novartis Commercial - Sanofi Aventis Commercial - Bayer Schering Commercial - Merck Serono Commercial - Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (C.W., A.K.M., M.S., T.D., L.N., G.M.z.H., H.-P.H., B.C.K.) and Institute for Virology (O.A.), Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; and the Department of Clinical Neuroscience (C.W., A.F.-H.), Karolinska Institutet, Stockholm, Sweden.
- Correspondence to Dr. Warnke: clemenswarnke{at}googlemail.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Fatal PML associated with efalizumab therapyInsights into integrin αLβ2 in JC virus controlN. Schwab, J.C. Ulzheimer, R.J. Fox et al.Neurology, February 01, 2012 -
Editorial
A bird's-eye view of T cells during natalizumab therapyReinhard Hohlfeld, Olaf Stüve et al.Neurology, September 18, 2013 -
Articles
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyP. Vermersch, L. Kappos, R. Gold et al.Neurology, May 16, 2011 -
Article
Impairment of JCV-specific T-cell response by corticotherapyEffect on PML-IRIS management?Caroline Antoniol, Samantha Jilek, Myriam Schluep et al.Neurology, November 21, 2012